Skip to main content
Erschienen in: Der Urologe 6/2018

16.04.2018 | Harnblasenkarzinom | Leitthema

Tumornachsorge des Harnblasenkarzinoms

Die richtigen Untersuchungen zum richtigen Zeitpunkt

verfasst von: PD Dr. P. Olbert, P. J. Goebell, A. Hegele

Erschienen in: Die Urologie | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Vorgaben zur Nachsorge des Harnblasenkarzinoms beruhen großteils auf Studien mit niedrigem Evidenzgrad und den daraus resultierenden, zumeist auf Expertenkonsens basierenden Empfehlungen der Leitlinien. Die Nachsorge des nicht-muskelinvasiven Harnblasenkarzinoms stützt sich auf Zystoskopie, Zytologie und in begrenztem Maße auf bildgebende Untersuchungen. Die Nachsorge des muskelinvasiven Urothelkarzinoms der Harnblase hängt in erster Linie von dem gewählten Therapieverfahren und vom Erkrankungsstadium ab. Die Nachsorge wird hier außerdem ergänzt durch funktionelle und die Lebensqualität betreffende Aspekte. Dies gilt in noch höherem Maße auch für die Gestaltung der Tumornachsorge in der Palliativsituation. Hier stehen individuell angepasst die Untersuchungen im Vordergrund, aus denen Konsequenzen für Lebensverlängerung und Symptomlinderung ableitbar sind.
Literatur
1.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465 (discussion 75–7)CrossRefPubMed Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465 (discussion 75–7)CrossRefPubMed
3.
Zurück zum Zitat Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R et al (2012) Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 89(1):61–66CrossRefPubMed Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R et al (2012) Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 89(1):61–66CrossRefPubMed
4.
Zurück zum Zitat Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 60(3):423–430CrossRefPubMed Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 60(3):423–430CrossRefPubMed
5.
Zurück zum Zitat Lammers RJ, Palou J, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA (2014) Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. BJU Int 114(2):193–201CrossRefPubMed Lammers RJ, Palou J, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA (2014) Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. BJU Int 114(2):193–201CrossRefPubMed
6.
Zurück zum Zitat Holmang S, Johansson SL (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 167(4):1634–1637CrossRefPubMed Holmang S, Johansson SL (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 167(4):1634–1637CrossRefPubMed
7.
Zurück zum Zitat Olsen LH, Genster HG (1995) Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl 172:33–36PubMed Olsen LH, Genster HG (1995) Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl 172:33–36PubMed
8.
Zurück zum Zitat Mariappan P, Smith G (2005) A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173(4):1108–1111CrossRefPubMed Mariappan P, Smith G (2005) A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173(4):1108–1111CrossRefPubMed
9.
Zurück zum Zitat Zieger K, Wolf H, Olsen PR, Hojgaard K (2000) Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85(7):824–828CrossRefPubMed Zieger K, Wolf H, Olsen PR, Hojgaard K (2000) Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85(7):824–828CrossRefPubMed
10.
Zurück zum Zitat Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM et al (1999) Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162(6):1946–1950CrossRefPubMed Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM et al (1999) Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162(6):1946–1950CrossRefPubMed
11.
Zurück zum Zitat Holmang S, Strock V (2012) Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? Eur Urol 61(3):503–507CrossRefPubMed Holmang S, Strock V (2012) Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? Eur Urol 61(3):503–507CrossRefPubMed
12.
Zurück zum Zitat Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170(2 Pt 1):438–441CrossRefPubMed Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170(2 Pt 1):438–441CrossRefPubMed
13.
Zurück zum Zitat Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 174(4 Pt 1):1238–1241CrossRefPubMed Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 174(4 Pt 1):1238–1241CrossRefPubMed
14.
Zurück zum Zitat Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E et al (2013) uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol 121(7):392–397CrossRefPubMed Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E et al (2013) uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol 121(7):392–397CrossRefPubMed
15.
Zurück zum Zitat Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP (2011) Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119–1123CrossRefPubMed Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP (2011) Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119–1123CrossRefPubMed
16.
Zurück zum Zitat Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A et al (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174(3):859–861 (discussion 61)CrossRefPubMed Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A et al (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174(3):859–861 (discussion 61)CrossRefPubMed
17.
Zurück zum Zitat Canales BK, Anderson JK, Premoli J, Slaton JW (2006) Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol 175(1):74–77CrossRefPubMed Canales BK, Anderson JK, Premoli J, Slaton JW (2006) Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol 175(1):74–77CrossRefPubMed
18.
Zurück zum Zitat Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, Nolte-Ernsting CC, Takahashi S, Cohan RH et al (2008) CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18(1):4–17CrossRefPubMed Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, Nolte-Ernsting CC, Takahashi S, Cohan RH et al (2008) CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18(1):4–17CrossRefPubMed
19.
Zurück zum Zitat Donat SM (2006) Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol 24(5):557–564CrossRefPubMed Donat SM (2006) Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol 24(5):557–564CrossRefPubMed
20.
Zurück zum Zitat Ghoneim MA, Abol-Enein H (2008) Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 5(9):501–508CrossRefPubMed Ghoneim MA, Abol-Enein H (2008) Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 5(9):501–508CrossRefPubMed
21.
Zurück zum Zitat Bochner BH, Montie JE, Lee CT (2003) Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 30(4):777–789CrossRefPubMed Bochner BH, Montie JE, Lee CT (2003) Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 30(4):777–789CrossRefPubMed
22.
Zurück zum Zitat Vrooman OP, Witjes JA (2010) Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol 20(5):437–442CrossRefPubMed Vrooman OP, Witjes JA (2010) Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol 20(5):437–442CrossRefPubMed
23.
Zurück zum Zitat Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN et al (2017) Systematic review on the fate of the remnant Urothelium after radical cystectomy. Eur Urol 71(4):545–557CrossRefPubMed Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN et al (2017) Systematic review on the fate of the remnant Urothelium after radical cystectomy. Eur Urol 71(4):545–557CrossRefPubMed
24.
Zurück zum Zitat Huguet J (2013) Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp 37(6):376–382CrossRefPubMed Huguet J (2013) Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp 37(6):376–382CrossRefPubMed
25.
Zurück zum Zitat Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S et al (2012) Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol 188(6):2046–2054CrossRefPubMed Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S et al (2012) Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol 188(6):2046–2054CrossRefPubMed
26.
Zurück zum Zitat Freeman JA, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC et al (1996) Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 156(5):1615–1619CrossRefPubMed Freeman JA, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC et al (1996) Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 156(5):1615–1619CrossRefPubMed
27.
Zurück zum Zitat Nieder AM, Sved PD, Gomez P, Kim SS, Manoharan M, Soloway MS (2004) Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 64(5):950–954CrossRefPubMed Nieder AM, Sved PD, Gomez P, Kim SS, Manoharan M, Soloway MS (2004) Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 64(5):950–954CrossRefPubMed
28.
Zurück zum Zitat Cho KS, Seo JW, Park SJ, Lee YH, Choi YD, Cho NH et al (2009) The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. Urol Int 82(3):306–311CrossRefPubMed Cho KS, Seo JW, Park SJ, Lee YH, Choi YD, Cho NH et al (2009) The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. Urol Int 82(3):306–311CrossRefPubMed
29.
Zurück zum Zitat Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81(9):2411–2416CrossRefPubMed Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81(9):2411–2416CrossRefPubMed
30.
Zurück zum Zitat Fernandez MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP et al (2012) The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol 30(6):821–824CrossRefPubMed Fernandez MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP et al (2012) The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol 30(6):821–824CrossRefPubMed
31.
Zurück zum Zitat Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW et al (2012) Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62(2):290–302CrossRefPubMed Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW et al (2012) Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62(2):290–302CrossRefPubMed
32.
Zurück zum Zitat Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W et al (2003) Long-term outcome of ileal conduit diversion. J Urol 169(3):985–990CrossRefPubMed Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W et al (2003) Long-term outcome of ileal conduit diversion. J Urol 169(3):985–990CrossRefPubMed
33.
Zurück zum Zitat Kalble T, Hofmann I, Thuroff JW, Stein R, Hautmann R, Riedmiller H et al (2012) Secondary malignancies in urinary diversions. Urologe A 51(4):500–502-6CrossRefPubMed Kalble T, Hofmann I, Thuroff JW, Stein R, Hautmann R, Riedmiller H et al (2012) Secondary malignancies in urinary diversions. Urologe A 51(4):500–502-6CrossRefPubMed
34.
Zurück zum Zitat Duerksen DR, Fallows G, Bernstein CN (2006) Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 22(11–12):1210–1213CrossRefPubMed Duerksen DR, Fallows G, Bernstein CN (2006) Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 22(11–12):1210–1213CrossRefPubMed
35.
Zurück zum Zitat Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161(4):1057–1066CrossRefPubMed Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161(4):1057–1066CrossRefPubMed
36.
Zurück zum Zitat Pattni S, Walters JR (2009) Recent advances in the understanding of bile acid malabsorption. Br Med Bull 92:79–93CrossRefPubMed Pattni S, Walters JR (2009) Recent advances in the understanding of bile acid malabsorption. Br Med Bull 92:79–93CrossRefPubMed
37.
Zurück zum Zitat Sapre N, Anderson P, Foroudi F (2012) Management of local recurrences in the irradiated bladder: a systematic review. BJU Int 110(Suppl 4):51–57CrossRefPubMed Sapre N, Anderson P, Foroudi F (2012) Management of local recurrences in the irradiated bladder: a systematic review. BJU Int 110(Suppl 4):51–57CrossRefPubMed
38.
Zurück zum Zitat Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF et al (2001) Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58(3):380–385CrossRefPubMed Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF et al (2001) Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58(3):380–385CrossRefPubMed
39.
Zurück zum Zitat Weiss C, Wittlinger M, Engehausen DG, Krause FS, Ott OJ, Dunst J et al (2008) Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70(5):1502–1506CrossRefPubMed Weiss C, Wittlinger M, Engehausen DG, Krause FS, Ott OJ, Dunst J et al (2008) Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70(5):1502–1506CrossRefPubMed
40.
Zurück zum Zitat Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR et al (2007) Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25(4):303–309CrossRefPubMed Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR et al (2007) Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25(4):303–309CrossRefPubMed
41.
Zurück zum Zitat Gamal El-Deen H, Elshazly HF, Zeina AEA (2009) Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer. J Egypt Natl Canc Inst 21(1):59–70PubMed Gamal El-Deen H, Elshazly HF, Zeina AEA (2009) Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer. J Egypt Natl Canc Inst 21(1):59–70PubMed
42.
Zurück zum Zitat Perdona S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L et al (2008) Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 112(1):75–83CrossRefPubMed Perdona S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L et al (2008) Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 112(1):75–83CrossRefPubMed
43.
Zurück zum Zitat Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R et al (2007) Radiochemotherapy with cisplatin and 5‑fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68(4):1072–1080CrossRefPubMed Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R et al (2007) Radiochemotherapy with cisplatin and 5‑fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68(4):1072–1080CrossRefPubMed
44.
Zurück zum Zitat Sabaa MA, El-Gamal OM, Abo-Elenen M, Khanam A (2010) Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 28(1):14–20CrossRefPubMed Sabaa MA, El-Gamal OM, Abo-Elenen M, Khanam A (2010) Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 28(1):14–20CrossRefPubMed
45.
Zurück zum Zitat Zapatero A, de Vidales MC, Arellano R, Bocardo G, Perez M, Rios P (2010) Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 28(4):368–374CrossRefPubMed Zapatero A, de Vidales MC, Arellano R, Bocardo G, Perez M, Rios P (2010) Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 28(4):368–374CrossRefPubMed
46.
Zurück zum Zitat George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C et al (2004) Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 64(3):488–493CrossRefPubMed George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C et al (2004) Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 64(3):488–493CrossRefPubMed
47.
Zurück zum Zitat Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I et al (2000) Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47(2):373–378CrossRefPubMed Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I et al (2000) Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47(2):373–378CrossRefPubMed
48.
Zurück zum Zitat Aboziada MA, Hamza HM, Abdlrahem AM (2009) Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst 21(2):167–174PubMed Aboziada MA, Hamza HM, Abdlrahem AM (2009) Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst 21(2):167–174PubMed
49.
Zurück zum Zitat Peyromaure M (2004) Simultaneous radio-chemotherapy: is it an alternative for cystectomy? Prog Urol 14(1 Suppl):11–13PubMed Peyromaure M (2004) Simultaneous radio-chemotherapy: is it an alternative for cystectomy? Prog Urol 14(1 Suppl):11–13PubMed
50.
Zurück zum Zitat Serretta V, Lo Greco G, Pavone C, Pavone-Macaluso M (1998) The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience. J Urol 159(4):1187–1191CrossRefPubMed Serretta V, Lo Greco G, Pavone C, Pavone-Macaluso M (1998) The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience. J Urol 159(4):1187–1191CrossRefPubMed
51.
Zurück zum Zitat Ikushima H, Iwamoto S, Osaki K, Furutani S, Yamashita K, Kawanaka T et al (2008) Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer. Radiat Med 26(3):156–163CrossRefPubMed Ikushima H, Iwamoto S, Osaki K, Furutani S, Yamashita K, Kawanaka T et al (2008) Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer. Radiat Med 26(3):156–163CrossRefPubMed
52.
Zurück zum Zitat Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E (2011) Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer 117(6):1190–1196CrossRefPubMed Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E (2011) Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer 117(6):1190–1196CrossRefPubMed
53.
Zurück zum Zitat Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM (2009) Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 74(2):511–517CrossRefPubMed Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM (2009) Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 74(2):511–517CrossRefPubMed
54.
Zurück zum Zitat Joung JY, Han KS, Kim TS, Seo HK, Chung J, Lee KH (2008) Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer. J Korean Med Sci 23(4):598–603CrossRefPubMedPubMedCentral Joung JY, Han KS, Kim TS, Seo HK, Chung J, Lee KH (2008) Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer. J Korean Med Sci 23(4):598–603CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Mohammed A, Hameed A, Shergill I, Barua J (2011) The practice of the first check cystoscopy following radiotherapy for the treatment of muscle-invasive (T3N0M0) bladder cancer: a UK national survey. Int Urol Nephrol 43(2):377–381CrossRefPubMed Mohammed A, Hameed A, Shergill I, Barua J (2011) The practice of the first check cystoscopy following radiotherapy for the treatment of muscle-invasive (T3N0M0) bladder cancer: a UK national survey. Int Urol Nephrol 43(2):377–381CrossRefPubMed
56.
Zurück zum Zitat Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158CrossRefPubMed Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158CrossRefPubMed
57.
Zurück zum Zitat Hassan JM, Cookson MS, Smith JA Jr., Chang SS (2006) Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol 175(6):2054–2057CrossRefPubMed Hassan JM, Cookson MS, Smith JA Jr., Chang SS (2006) Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol 175(6):2054–2057CrossRefPubMed
58.
Zurück zum Zitat Eisenberg MS, Thompson RH, Frank I, Kim SP, Cotter KJ, Tollefson MK et al (2014) Long-term renal function outcomes after radical cystectomy. J Urol 191(3):619–625CrossRefPubMed Eisenberg MS, Thompson RH, Frank I, Kim SP, Cotter KJ, Tollefson MK et al (2014) Long-term renal function outcomes after radical cystectomy. J Urol 191(3):619–625CrossRefPubMed
59.
Zurück zum Zitat Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I (2011) Long-term complications of conduit urinary diversion. J Urol 185(2):562–567CrossRefPubMed Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I (2011) Long-term complications of conduit urinary diversion. J Urol 185(2):562–567CrossRefPubMed
60.
Zurück zum Zitat Hautmann RE, de Petriconi RC, Volkmer BG (2011) 25 years of experience with 1,000 neobladders: long-term complications. J Urol 185(6):2207–2212CrossRefPubMed Hautmann RE, de Petriconi RC, Volkmer BG (2011) 25 years of experience with 1,000 neobladders: long-term complications. J Urol 185(6):2207–2212CrossRefPubMed
Metadaten
Titel
Tumornachsorge des Harnblasenkarzinoms
Die richtigen Untersuchungen zum richtigen Zeitpunkt
verfasst von
PD Dr. P. Olbert
P. J. Goebell
A. Hegele
Publikationsdatum
16.04.2018
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 6/2018
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-018-0641-3

Weitere Artikel der Ausgabe 6/2018

Der Urologe 6/2018 Zur Ausgabe

Termine

Termine

Mitteilungen der DGU

Mitteilungen der DGU

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.